论文部分内容阅读
目的 :探讨伊贝沙坦联合培哚普利治疗慢性充血性心力衰竭 (CHF)的临床疗效。方法 :6 4例CHF患者随机分成治疗组和对照组。治疗组 34例给予伊贝沙坦 15 0mg/d ,培哚普利 4mg/d ;对照组给予培哚普利 4mg/d及安慰剂治疗。两组基础治疗类同 ,疗程 6个月。观察治疗前后两组患者的临床症状 ,超声心动图心功能指标 ,6min步行距离的变化及不良反应。结果 :治疗后 ,治疗组临床总有效率为 88.2 4 % ,对照组总有效率为80 .0 0 % ;两组治疗前后相比左室射血分数 (LVEF)、每搏量、心脏指数 (CI)、6min步行距离均有显著改善 (P <0 .0 1) ,治疗组LVEF、CI及 6min步行距离的改善优于对照组。结论 :伊贝沙坦联合培哚普利治疗CHF可以增强疗效。
Objective: To investigate the clinical efficacy of irbesartan combined with perindopril in the treatment of chronic congestive heart failure (CHF). Methods: Sixty-four CHF patients were randomly divided into treatment group and control group. The treatment group 34 cases were given irbesartan 150mg / d, perindopril 4mg / d; the control group was given perindopril 4mg / d and placebo treatment. The same two groups of basic treatment, treatment for 6 months. Clinical symptoms, echocardiographic cardiac function, changes in walking distance 6min and adverse reactions were observed before and after treatment. Results: After treatment, the total clinical effective rate was 88.2% in the treatment group and 80.0% in the control group. The levels of left ventricular ejection fraction (LVEF), stroke volume, cardiac index CI), 6min walk distance (P <0.01). The improvement of LVEF, CI and 6min walk distance in the treatment group was better than that in the control group. Conclusion: Irbesartan combined with perindopril can improve the curative effect of CHF.